The Oncology Institute, Inc.
The Oncology Institute, Inc. (TOI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
toi · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$8.00
+55.0% upside
Low
$8.00
Median: $8 · Last Close: $5.16
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.42 | ↑ 5.00% |
1-day model range: $5.38–$5.46. Peak: $5.46 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $9 | +79.8% |
| 2028 | $13 | +158.7% |
| 2029 | $17 | +221.1% |
| 2030 | $19 | +263.7% |
| 2031 | — | +290.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TOI · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-13 | Needham | Maintains | Buy→Buy |
| 2026-03-13 | B. Riley Securities | Maintains | Buy→Buy |
| 2026-03-09 | Needham | Maintains | Buy→Buy |
| 2026-03-09 | BTIG | Maintains | Buy→Buy |
| 2025-10-21 | BTIG | Maintains | Buy→Buy |
| 2023-06-16 | Guggenheim | Maintains | Buy→Buy |
| 2023-03-20 | Guggenheim | Maintains | Neutral→Neutral |
| 2022-11-11 | Guggenheim | Maintains | Buy→Buy |
| 2022-08-15 | Jefferies | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on The Oncology Institute, Inc. (TOI) stock. Of the recent 9 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover TOI.
Analyst Recommendation Trends
TOI analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 4 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$415M
↓ 36.7% YoY
Revenue Next Year
$501M
↑ 20.7% YoY
EPS This Year
$-0.36
EPS Next Year
$-0.59
↑ 63.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast TOI EPS of $-0.36 for the current fiscal year, based on estimates from 1 analysts. The TOI revenue forecast is $415M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TOI stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TOI price target is $8.00 (+55.0% upside), with an analyst consensus of Buy.
The TOI short-term stock prediction for tomorrow is $5.42 (+5.00%). The TOI stock price prediction for 2027 estimates an average of $9. The TOI stock prediction for 2030 projects a range of $17–$20.
The Oncology Institute, Inc. trades on NASDAQ under the ticker TOI. The TOI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
TOI forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month TOI price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +55.0% potential upside from the current price of $5.16.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.